StreetInsider.com News Articles

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed an agreement with Spaulding Rehabilitation (“Spaulding Rehabilitation”), a member of the Mass General Brigham healthcare system, for the provision of MDMA for use in a clinical trial investigating MDMA-assisted therapy for the treatment of fibromyalgia.

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

Thu, 26 Feb 2026 08:26:00 -0500

Under the agreement, PharmAla will provide its LaNeo™ MDMA at no charge to Spaulding Rehabilitation for use in a study

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed a binding supply agreement with Amsterdam University Medical Center (“Amsterdam UMC”) in the Netherlands for the provision of LaNeo™ 40mg MDMA capsules for use in a proposed clinical trial.

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Mon, 23 Feb 2026 08:30:00 -0500

Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year

PharmAla appoints Lennie Ryer to board, accepts Slassi resignation

Tue, 10 Feb 2026 16:40:12 -0500

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced changes to its board of directors effective February 9, 2026. The biotechnology company accepted the resignation of Dr. Malik Slassi and appointed Lennie Ryer, CPA, CA, to its board.

Nicholas Kadysh, PharmAla's CEO, said Dr. Slassi was among the first people he approached when PharmAla was in its initial stages. "We are immeasurably grateful for his support and insight over the past 4 years," Kadysh stated in the company's announcement.

Ryer brings financial executive and board director experience from the pharmaceutical, biotechnology, and technology sectors. He has served as Chief Financial Officer and

PharmAla appoints Lennie Ryer to board, accepts Slassi resignation

Tue, 10 Feb 2026 16:40:12 -0500

Ryer brings financial executive and board director experience from the pharmaceutical, biotechnology, and technology sectors. He has served as Chief Financial Officer and

PharmAla appoints Lennie Ryer to board, accepts Slassi resignation

Tue, 10 Feb 2026 16:40:12 -0500

Ryer brings financial executive and board director experience from the pharmaceutical, biotechnology, and technology sectors. He has served as Chief Financial Officer and

PharmAla appoints Lennie Ryer to board, accepts Slassi resignation

Tue, 10 Feb 2026 16:40:12 -0500

Ryer brings financial executive and board director experience from the pharmaceutical, biotechnology, and technology sectors. He has served as Chief Financial Officer and

PharmAla appoints Lennie Ryer to board, accepts Slassi resignation

Tue, 10 Feb 2026 16:40:12 -0500

Ryer brings financial executive and board director experience from the pharmaceutical, biotechnology, and technology sectors. He has served as Chief Financial Officer and